Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Ocrevus in Relapsing Multiple Sclerosis
NCT03853746Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Apr 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Johns Hopkins University. Primary endpoint: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion at 27 months. Started Apr 2019; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03853746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03853746.